Products - Liver cancers | Topic

Showing 31 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 July 2024
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 July 2024
Published:
31 March 2021
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 April 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 January 2024
Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2020
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 October 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 December 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 July 2024
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Liver cancers Products

Filter

Product type

Guidance programme
1 selected

Status

New and updated

Showing 31 products

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (TA985)

Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)

Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]

Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]

Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]

Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]

Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6146

Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117

Liver cancers Products

Filter

Product type

Guidance programme1 selected

Status

New and updated

Showing 31 products

Guidance programme
1 selected